KPTI KPTI
Company Profile ↓Company Overview
KPTI (KPTI) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 66.9%, reflecting efficient use of shareholder capital.
Revenue has grown at a 63.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $146.07M (+0.6% YoY); net profit $-196.04M.
- Trailing 12 Months Year-on-year growth — revenue +0.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 63.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 63.32% |
| 1 Year: | 0.57% |
Stock Price Performance
| 1 Year: | -52.49% |
| 6 Months: | -70.84% |
| 3 Months: | -79.70% |
| 1 Month: | -81.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)16.31 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 66.9%.
- Compounding revenue at 63.3% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 82.1% below its 52-week high.
- RSI at 16 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 3.00K | - | - | 10.00M | 19.89M | 239.00K | - | 155.00K | 9.49M | 13.15M | 18.14M | 33.51M | 21.33M | 23.26M | 22.60M | 37.69M | 47.67M | 39.68M | 36.15M | 38.70M | 37.58M | 36.01M | 33.13M | 42.79M | 38.78M | 30.02M | 37.93M | 44.04M | 35.07M |
| Operating Income | -19.74M | -25.94M | -26.15M | -33.01M | -30.61M | -29.30M | -27.35M | -30.48M | -25.74M | -27.16M | -30.28M | -29.75M | -31.05M | -39.45M | -38.94M | -34.33M | -49.15M | -57.45M | -64.92M | -41.69M | -39.40M | -47.36M | -40.32M | -47.11M | -52.37M | -49.05M | -43.81M | -34.59M | -42.91M | -30.84M | -30.90M | -29.57M | -31.26M | -33.76M | -28.12M | -26.28M | -33.26M | -24.39M | -15.22M | -26.76M |
| Net Income | -19.72M | -25.93M | -26.07M | -32.70M | -30.37M | -29.05M | -27.06M | -30.16M | -25.43M | -26.93M | -29.92M | -29.39M | -30.64M | -39.04M | -38.46M | -33.66M | -48.08M | -58.21M | -66.16M | -43.41M | -41.37M | -52.93M | -46.43M | -53.49M | -57.41M | -53.58M | -51.81M | -41.40M | -49.06M | -36.32M | -34.13M | -32.63M | -34.51M | -37.36M | 23.79M | -32.07M | -23.46M | -37.25M | -33.13M | -22.39M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.71 | -0.69 | -0.53 | -0.62 | -0.45 | -0.30 | -0.29 | -0.30 | -4.85 | -2.97 | -3.85 | -2.77 | -4.32 | -3.82 | -1.24 |
| R&D Expense | 15.95M | - | 20.75M | 27.01M | 25.92M | - | 21.80M | 24.58M | 19.89M | - | 24.08M | 23.12M | 25.24M | - | 41.32M | 44.73M | 36.43M | - | 37.97M | 26.52M | 26.27M | 34.00M | 42.59M | 37.04M | 37.05M | 33.98M | 45.81M | 42.06M | 44.31M | 31.36M | 32.34M | 31.48M | 35.55M | 35.42M | 38.37M | 36.13M | 34.62M | 32.79M | 30.54M | 33.80M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 152.00K | 634.00K | 387.00K | 229.00K | 250.00K | 154.00K | 1.60M | 30.34M | 40.89M | 108.08M | 209.82M | 157.07M | 146.03M | 145.24M | 146.07M |
| Operating Income | - | - | -10.31M | -15.89M | -33.95M | -75.85M | -119.08M | -110.73M | -130.54M | -179.88M | -189.28M | -171.85M | -98.27M | -142.20M | -129.54M | -119.44M | -90.71M |
| Net Income | -179.00K | -2.24M | -10.31M | -15.89M | -33.95M | -75.78M | -118.18M | -109.58M | -128.98M | -178.41M | -199.59M | -196.27M | -124.09M | -165.29M | -143.10M | -76.42M | -196.04M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -2.72 | -1.65 | -2.02 | -18.79 | -14.00 | -17.93 |
| R&D Expense | - | - | 8.62M | 14.10M | 28.45M | 60.13M | 97.74M | 86.94M | 107.27M | 161.37M | 122.34M | 150.81M | 160.84M | 148.66M | 138.75M | 143.23M | 125.62M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 1.31M | 158.23M | 220.34M | 215.44M | 180.38M | 180.29M | 341.19M | 294.96M | 313.05M | 305.31M | 358.17M | 240.44M | 164.42M | 108.42M |
| Total Equity | -179.00K | -2.38M | -12.65M | -27.88M | 154.93M | 206.79M | 198.37M | 162.24M | 129.46M | 183.17M | 49.77M | 50.55M | -79.67M | -16.66M | -136.21M | -186.02M | -292.93M |
| Cash & Equivalents | - | 3.44M | 6.51M | 391.00K | 155.97M | 150.61M | 58.36M | 49.66M | 69.00M | 118.02M | 128.86M | 85.92M | 190.46M | 135.19M | 52.23M | 62.48M | 60.54M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | 169.29M | - | - | - | - |
| Total Liabilities | - | - | - | - | 3.29M | 13.54M | 17.08M | 18.14M | 50.83M | 158.02M | 245.19M | 262.50M | 384.98M | 374.83M | 376.64M | 350.44M | 401.34M |
| Current Liabilities | - | - | - | 1.93M | 3.29M | 12.30M | 15.13M | 16.48M | 49.47M | 46.90M | 46.35M | 60.20M | 73.72M | 65.91M | 69.48M | 92.26M | 92.06M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | -84.39M | -73.72M | -159.12M | -190.82M | -160.23M | -107.12M | -149.55M | -92.72M | -127.49M | -75.37M |
| Investing Cash Flow | - | - | - | - | - | 24.59M | 17.11M | -107.66M | 78.45M | -53.69M | 141.84M | -104.26M | 7.94M | 95.47M | 43.38M |
| Financing Cash Flow | - | - | - | - | - | 51.16M | 75.74M | 316.11M | 124.31M | 172.08M | 73.65M | 193.74M | 1.12M | 41.65M | 30.05M |
| Capital Expenditure | -376.00K | -121.00K | -57.00K | -2.83M | -1.42M | -70.00K | -62.00K | -2.36M | -206.00K | -145.00K | -212.00K | -118.00K | -0 | -142.00K | -0 |
| Free Cash Flow | - | - | - | - | - | -84.46M | -73.78M | -161.48M | -191.03M | -160.38M | -107.33M | -149.67M | -92.72M | -127.63M | -75.37M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -6,783.6% | -2,506.3% | -8,772.6% | -33,120.5% | -47,630.4% | -71,903.9% | -8,133.2% | -593.0% | -462.9% | -159.0% | -46.8% | -90.5% | -88.7% | -82.2% | -62.1% |
| Net Margin % | - | - | -6,783.6% | -2,506.0% | -8,771.8% | -33,090.4% | -47,272.4% | -71,153.9% | -8,036.4% | -588.1% | -488.1% | -181.6% | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% |
| ROE % | 100.0% | 94.4% | 81.5% | 57.0% | -21.9% | -36.6% | -59.6% | -67.5% | -99.6% | -97.4% | -401.0% | -388.3% | 155.7% | 992.4% | 105.1% | 41.1% | 66.9% |
| ROCE % | - | - | - | 2,567.0% | -21.9% | -36.5% | -59.4% | -67.6% | -99.8% | -61.1% | -76.1% | -68.0% | -42.4% | -48.7% | -75.8% | -165.5% | -554.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KPTI
Why Is KPTI Stock Down 69% After-Hours Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPbk04MUZMTDhwVGVETzhuZ1dGQklrbmpON0lSX3pSSmhETVNXQWJ2UWVqS3F4MTV0Z2FyNlFMbTJWcnZKb2tzaFBUMENWRG5oNmVxOUV0RFFVcDNfa0tfVlJBaDd3QzlWeXU3Si1ZeW5ZM1lvVkRXc0puUm15cVFZUER2QnhMdGVHMmNZZ2…
$KPTI stock is down 67% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOeHowc3hNV1BUVVNOUmRDZVBkR0VEYVpCY19PUFdjak9PdnZvdUpMRDIxcWFfTFZvQkV6cjNnMThCYWxJdXZPQTVqTXhad0MxaS1jeDc0M09IeWhxek9PWDdBckx6Um9HLXowc0hwQmpRX2ptQmtKMkdjam4xWXNienRmM3JYV25EQzNRMD…
Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOd2NPYkRxak5DWF9XRUJzMHYyN09ES2NSd0Jmd0J2eG1iN3ltS0xDVkJGUkJEVjFKU3ZQLUVCbkJnTzFPU1JaSEVHblRKeEFlSTlGMFVLanExdFdrZS1zWEM1WE5kdU1mQXFjdl9NMEVCNGRCeE1ETnFIOHJDRmNLMEZ6V1VUQmxUWGtFUm…
KPTI Stock Collapses After Trial Failure And Legal Scrutiny - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxNaVk3aGEwcGdjNm5LdFdxX1J2T0JkOC1TM3ozVGpVWUxydlhXN1NyY0VUaS1VampGUkhSZ0FaNjAydWVid25xSnRTN2phaEFTY3NsdTJNc1Z0eGVDMk5jOFNCSURNTmp1RDRzbUdPeWZ1WmV0M0l5VVMxQXZGWFI1d3V5U2FUY0U?oc=5" …
Market Movers | Winners: FWAC, REPL, MGRX | Losers: KPTI, BIOA, MBRX - Trefis
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQXzBCRUREcDlWY0c1eXFTMDlSWUQydGFPdUFkTnFlclRqdV9sRnF3R0ZGOGp0aWZEWnhMaTdXcnVuQXV4cDdkbklQMEJXOFo3NFFqam16ZC1vTXVOcWwxX0pfNEEtenNaZ1RKZVlQcUtTdHc2MzF1T2tGMllYMVMtWEZ0dG1aZWszLTBBZl…
Karyopharm Stock (KPTI) Crashes After Hours: Here's What's Driving the Move - TradingView
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNNTNlNFJWa3l3SEZtQkZvUWRwSTFTMEVGWkhsT3p1amgtb3BhdHdoN2Z2dElRcGQ4N2Y5WG54RlBZeUhZVU9sa3dwdEtUYjBsUlYwV3pvb1hwa2JCNGw2QWFNNEYwdVhXWmtVb05GMldiRGk1VGx1Q3JWVXZKV1R3enFpZU9FUzdCSEYzZT…
KPTI — Frequently Asked Questions
What is the current share price of KPTI?
As of 2026-08-05 17:25 PDT, KPTI trades at $1.91 on NASDAQ/NYSE. Its 52-week range is $1.91 to $10.67.
What is the P/E ratio of KPTI?
KPTI trades at a trailing price-to-earnings (P/E) ratio of -0.11.
What is the return on equity (ROE) of KPTI?
KPTI has a return on equity (ROE) of 66.92%.
Is KPTI a good stock to buy?
This page provides a data-driven analysis of KPTI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.